SCYNEXIS Agrees With Poxel To Acquire PXL-770; $8M Upfront, Up To $188M Milestones

SCYNEXIS, Inc. has entered into a definitive agreement to acquire PXL-770 from Poxel S.A. for an upfront payment of $8 million, with potential future payments totaling up to $188 million based on development and commercial milestones. PXL-770, now designated as SCY-770, is an oral therapy aimed at treating ADPKD and has received Orphan Drug Designation from the FDA. SCYNEXIS plans to initiate a Phase 2 proof-of-concept study in Q4 2026, with an expected early efficacy readout in the second half of 2027.